Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 1,904 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: AstraZeneca Clear all

Conditions: Resistant Hypertension
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Surprise, Arizona • Hollywood, Florida • Lake Worth, Florida + 13 more

Conditions: Primary Hyperaldosteronism
Interventions: Baxdrostat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Arthritis
Interventions: Blood samples, Synovial fluid aspiration, Synovial tissue sample; Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Frederick, Maryland • Wyomissing, Pennsylvania • Jackson, Tennessee

Conditions: Eosinophilic Esophagitis
Interventions: inhaled/swallowed budesonide, viscous/swallowed budesonide; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cities in Georgia, Georgia

Conditions: Non-Small-Cell Lung Carcinoma NSCLC
Interventions: MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 35
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 28 more

Conditions: Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions: Durvalumab, FLOT chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 200 Years
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sylmar, California + 12 more

Conditions: Supportive Care
Interventions: D-SCAN; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers, Pharmacologic Action
Interventions: AZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 20 more

Conditions: Healthy
Interventions: AZD1722, Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Asthma
Interventions: Benralizumab (Medi-563), Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 100
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more

Conditions: GERD
Interventions: esomeprazole 40 mg; Drug
Lead sponsor: David A. Johnson, MD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions: DS-8201a, T-DM1; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 126
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more

Conditions: Lymphoma, NHL, Non-Hodgkin Lymphoma
Interventions: AZD4877; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: New York, New York • Philadelphia, Pennsylvania • Greenville, South Carolina

Conditions: Weight Management
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 56
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more

Conditions: Hepatic Impairment
Interventions: Mitiperstat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Orlando, Florida + 2 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 73 more

Conditions: Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Interventions: MEDI4736, MEDI4736 + Tremelimumab, Standard of Care; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 23
States / cities: Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 6,263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 66
States / cities: Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more

Conditions: Nonalcoholic Steatohapatitis
Interventions: Roflumilast, Pioglitazone, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Coronado, California • Annapolis, Maryland • Baltimore, Maryland

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 12
States / cities: Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more

Conditions: Bioavailability, B-cell Lymphoid Cancer
Interventions: Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Digital Supportive Care Awareness & Navigation

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects